AGL 38.02 Increased By ▲ 0.08 (0.21%)
AIRLINK 197.36 Increased By ▲ 3.45 (1.78%)
BOP 9.54 Increased By ▲ 0.22 (2.36%)
CNERGY 5.91 Increased By ▲ 0.07 (1.2%)
DCL 8.82 Increased By ▲ 0.14 (1.61%)
DFML 35.74 Decreased By ▼ -0.72 (-1.97%)
DGKC 96.86 Increased By ▲ 4.32 (4.67%)
FCCL 35.25 Increased By ▲ 1.28 (3.77%)
FFBL 88.94 Increased By ▲ 6.64 (8.07%)
FFL 13.17 Increased By ▲ 0.42 (3.29%)
HUBC 127.55 Increased By ▲ 6.94 (5.75%)
HUMNL 13.50 Decreased By ▼ -0.10 (-0.74%)
KEL 5.32 Increased By ▲ 0.10 (1.92%)
KOSM 7.00 Increased By ▲ 0.48 (7.36%)
MLCF 44.70 Increased By ▲ 2.59 (6.15%)
NBP 61.42 Increased By ▲ 1.61 (2.69%)
OGDC 214.67 Increased By ▲ 3.50 (1.66%)
PAEL 38.79 Increased By ▲ 1.21 (3.22%)
PIBTL 8.25 Increased By ▲ 0.18 (2.23%)
PPL 193.08 Increased By ▲ 2.76 (1.45%)
PRL 38.66 Increased By ▲ 0.49 (1.28%)
PTC 25.80 Increased By ▲ 2.35 (10.02%)
SEARL 103.60 Increased By ▲ 5.66 (5.78%)
TELE 8.30 Increased By ▲ 0.08 (0.97%)
TOMCL 35.00 Decreased By ▼ -0.03 (-0.09%)
TPLP 13.30 Decreased By ▼ -0.25 (-1.85%)
TREET 22.16 Decreased By ▼ -0.57 (-2.51%)
TRG 55.59 Increased By ▲ 2.72 (5.14%)
UNITY 32.97 Increased By ▲ 0.01 (0.03%)
WTL 1.60 Increased By ▲ 0.08 (5.26%)
BR100 11,727 Increased By 342.7 (3.01%)
BR30 36,377 Increased By 1165.1 (3.31%)
KSE100 109,513 Increased By 3238.2 (3.05%)
KSE30 34,513 Increased By 1160.1 (3.48%)
Business & Finance

Russia's Sputnik V developers to sue Brazilian regulator for 'false information' about their vaccine

  • The board of Brazilian health regulator on Monday rejected importing Sputnik V after technical staff warned of flaws in its development along with incomplete data regarding the vaccine's safety and efficacy.
  • A crucial issue for the Brazilian regulator was the risk of other viruses used to make the vaccine reproducing in patients, which an Anvisa expert had called a "serious" defect.
Published April 29, 2021

MOSCOW: Russian developers of the Sputnik V vaccine against COVID-19 said on Thursday that they were suing Brazilian regulator Anvisa for defamation, accusing it of having knowingly spread false information without testing their product.

The board of Brazilian health regulator on Monday rejected importing Sputnik V after technical staff warned of flaws in its development along with incomplete data regarding the vaccine's safety and efficacy.

A crucial issue for the Brazilian regulator was the risk of other viruses used to make the vaccine reproducing in patients, which an Anvisa expert had called a "serious" defect.

Sputnik V's official Twitter account on Thursday cited a Brazilian media story citing the same expert as saying that no tests had been carried out to test the Brazilian theory.

"Following the admission of Brazilian regulator Anvisa that it did not test Sputnik V vaccine, Sputnik V is undertaking a legal defamation proceeding in Brazil against Anvisa for knowingly spreading false and inaccurate information," it said.

"Anvisa made incorrect and misleading statements without having tested the actual Sputnik V vaccine."

Comments

Comments are closed.